All Articles

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

In a strategic pivot, GeneDx brings in former Quest and Thermo Fisher exec Mark Gardner to translate its genomic leadership into commercial dominance.

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

As new federal work rules loom for Indiana's Medicaid members, MHS is investing millions in a workforce program. Is it a proactive lifeline or a new corporate playbook?

Conifer's oversubscribed fund isn't just about the money. It's a massive wager on a leader's proven playbook for building the core assets of our new economy.

As AI-driven attacks escalate, BreachRx adds Phil Venables to its board, signaling a critical shift in how enterprises must manage cyber crises.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

A $25M deal is funding a luxury manufacturer's expansion, revealing a larger story about shifting supply chains and the global appetite for affordable luxury.

A new wave of investment aims to shield America's industrial backbone from cyber threats, bringing modern software discipline to the factory floor.

A new tool lets AI agents and developers test an app's hidden plumbing using plain English, signaling a major shift in software quality engineering.

A construction firm is merging with an AI robotics leader to go public. The deal, backed by high-profile investors, is built on a new patent that could redefine autonomous warfare and create opportunities far beyond the battlefield.

With its new stablecoin reserve fund, State Street isn't just launching a product. It's forging a regulated path where traditional finance and digital currency finally meet.

A small med-tech firm is betting its future on fingerprint sweat. Can its novel drug test pass the FDA's rigorous trials and disrupt a billion-dollar market?

Beyond a simple rebrand, CTM's new integrations and strategic hires reveal a deeper play to solve the market's biggest data disconnect for modern business.

A new partnership highlights how regulatory pressure and data analytics are forcing skilled nursing facilities to adopt tech for safer, more efficient patient care.

California Resources Corporation is swapping old debt for new. We dive into how this $550M move bolsters its balance sheet and fuels its carbon-cutting ambitions.

A new partnership aims to transform care for thousands of dual-eligible residents, moving specialized palliative services from the hospital to the community.

A craft tequila partners with the Cubs, but this is more than a new ballpark drink. It’s a calculated signal of where sports marketing and consumer tastes are headed.

Amid soaring costs and licensing chaos from market incumbents, Opti9's exclusive deal to distribute Virtuozzo offers a critical lifeline to North American firms.

A new partnership between IS3WARE and Privacy Horizon signals a pivotal shift in how our most sensitive sectors will defend against digital and regulatory threats.